Experienced in Chromosome 8p Deletion

Massimo Breccia

Rome, IT 
Experienced in Chromosome 8p Deletion
Rome, IT 
OverviewLocationsClinical Research

Overview

Massimo Breccia practices in Rome, Italy. Mr. Breccia is rated as an Experienced expert by MediFind in the treatment of Chromosome 8p Deletion. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Leukemia, Acute Promyelocytic Leukemia, Myelofibrosis, and Bone Marrow Transplant.

His clinical research consists of co-authoring 516 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Chromosome 8p Deletion.

Gender
Male

Locations

Rome, Italy
Other Locations
Sapienza, Italy
Gruppo, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.
Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.
Enrollment Status: Completed
Publish Date: April 18, 2025
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Enrollment Status: Unknown
Publish Date: January 20, 2022
Intervention Type: Drug
Study Drugs: Imatinib, Nilotinib
Study Phase: Phase 4
An International Field Study for the Reliability and Validity of the Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia (EORTC QLQ-CML24)
An International Field Study for the Reliability and Validity of the Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia (EORTC QLQ-CML24)
Enrollment Status: Unknown
Publish Date: March 21, 2019
Mid to Long-term Quality of Life Effects Of imatiNIb Versus DASatinib in Chronic Myeloid Leukemia Patients (LEONIDAS)
Mid to Long-term Quality of Life Effects Of imatiNIb Versus DASatinib in Chronic Myeloid Leukemia Patients (LEONIDAS)
Enrollment Status: Unknown
Publish Date: August 06, 2018
Intervention Type: Other
View 3 Less Clinical Trials

516 Total Publications

Clinical Relevance and Prognostic Value of the Triple A (AAA) Score in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX).
Clinical Relevance and Prognostic Value of the Triple A (AAA) Score in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX).
Journal: European journal of haematology
Published: August 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Breccia's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 18 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile